JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech’s 2024 sales surged 342% YoY, driven by a Takeda payment.
JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech’s 2024 sales surged 342% YoY, driven by a Takeda payment.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.